Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model
Open Access
Abstract
Background: ZR2002 is a dual EGFR-DNA-targeting combi-molecule that carries a chloroethyl group at the six-position of the quinazoline ring designed to alkylate DNA. Despite its good pharmacokinetics, ZR2002 is metabolized in vivo into dechlorinated metabolites, losing the DNA-alkylating function required to damage DNA. To increase the DNA damage activity in tumor cells in vivo, we compared ZR2002 with two of its 6-N,N-disubstituted analogs: “JS61”, with a nitrogen mustard function at the six-position of the quinazoline ring, and “JS84”, with an N-methyl group. Methods: Tumor xenografts were performed with the human Saos-2 osteosarcoma cell line expressing EGFR. Mice were treated with ZR2002, JS84 or JS61, and the tumor burden was measured with a caliper and CT/PET imaging. Drug metabolism was analyzed with LC-MS. EGFR and ɣ-H2AX phosphorylation were quantified via Western blot analysis and immunohistochemistry. Results: In vivo analysis showed that significant tumor growth inhibition was only achieved when ZR2002 was administered in its naked form. The metabolic dealkylation of JS61 and JS84 did not release sufficient concentrations of ZR2002 for the intratumoral inhibition of P-EGFR or enhanced levels of P-H2AX. Conclusions: The results in toto suggest that intratumoral concentrations of intact ZR2002 are correlated with the highest inhibition of P-EGFR and induction of DNA damage in vivo. ZR2002 may well represent a good drug candidate for the treatment of EGFR-expressing osteosarcoma.Keywords
Funding Information
- MUHC Cancer Care Mission/MGH Foundation (RI-MUHC)
- Cedars Cancer Foundation (RI-MUHC)
- MUHC Foundation (RI-MUHC)
- Research Institute of the McGill University Health Centre (RI-MUHC)
This publication has 42 references indexed in Scilit:
- The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with OsteosarcomaInternational Journal of Molecular Imaging, 2012
- Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?Cancer Research and Treatment, 2012
- A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR–DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activityJournal of Pharmaceutical and Biomedical Analysis, 2011
- Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2Bioorganic & Medicinal Chemistry Letters, 2009
- Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomasGenes, Chromosomes and Cancer, 2008
- Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical OutcomeClinical Cancer Research, 2007
- Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR statusBioorganic & Medicinal Chemistry Letters, 2005
- The Combi-Targeting Concept: Dissection of the Binary Mechanism of Action of the Combi-Triazene SMA41 in Vitro and Antitumor Activity in VivoThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell lineThe Prostate, 2003
- The Combi-Targeting Concept: Chemical Dissection of the Dual Targeting Properties of a Series of “Combi-Triazenes”Journal of Medicinal Chemistry, 2003